Industry-specific and extensively researched technical data (partially from exclusive partnerships).
A paid subscription is required for full access.
Savings through generic drug usage in the U.S. 2008-2018
Savings through generic drug usage in the United States from 2008 to 2018 (in billion U.S. dollars)
In 2018, the healthcare system in the United States saved some 293 billion U.S. dollars via the usage of generic drugs. Over a 10-year period (2009-2018), the U.S. saved about two trillion U.S. dollars through generic drugs.
Savings through generic drug usage in the United States from 2008 to 2018 (in billion U.S. dollars)
| Savings in billion U.S. dollars | |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| Savings in billion U.S. dollars | |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
© Statista 2019
About this statistic
Show source
Please be patient - this may take a moment
Description
Source
More information
- Show sources information
- Show publisher information
- Release date
- 2019
- Region
- United States
- Survey time period
- 2008 to 2018
- Supplementary notes
- This statistic was assembled from several of AAM's drug access and savings reports.
- Open this statistic in...
Source
- Show sources information
- Show publisher information
- Release date
- 2019
More information
- Region
- United States
- Survey time period
- 2008 to 2018
- Supplementary notes
- This statistic was assembled from several of AAM's drug access and savings reports.
- Open this statistic in...
Other statistics on the topic
Pharmaceutical Industry in the U.S.
+Pharmaceutical Products & Market
Pharmaceutical market: worldwide revenue 2001-2018
+Pharmaceutical Products & Market
Revenues of leading global generics manufacturers 2018
+Pharmaceutical Products & Market
U.S. brand and generic prescription drug revenue 2005-2018
+Pharmaceutical Products & Market
Pfizer's revenue by segment 2014-2018
You only have access to basic statistics.
This statistic is not included in your account!
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$49 / Month *
Corporate solution including all features.
Prices do not include sales tax.
All Information
in one Presentation
- 82 page/s
- English
- pptx
- Detailed references
Everything On "Generics and biosimilars" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.
I think of Statista as Google for researchers. Statista provides you with the information you search for right away.Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation
- Global overview
- Revenue of the worldwide pharmaceutical market from 2001 to 2018 (in billion U.S. dollars)Pharmaceutical market: worldwide revenue 2001-2018
- Worldwide total generic prescription drug revenue from 2010 to 2024 (in billion U.S. dollars)Total worldwide generic prescription drug revenue 2010-2024
- Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2010 to 2024Global generic prescription drug revenues as share of prescribed revenue 2010-2024
- Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*Patent expiration risks for total worldwide prescription drug revenue 2010-2024
- Top companies
- Top generics manufacturers based on revenue in 2018 (in billion U.S. dollars)*Revenues of leading global generics manufacturers 2018
- Generic revenues of Teva Pharmaceutical Industries from 2016 to 2018, by region (in million U.S. dollars)Teva Pharmaceutical Industries' generic revenues by region 2016-2018
- Novartis AG's revenue from 2014 to 2018, by segment (in billion U.S. dollars)Novartis revenue 2014-2018 by segment
- Pfizer's revenue in 2014 and 2018, by segment (in million U.S. dollars)*Pfizer's revenue by segment 2014-2018
- U.S. market
- Brand and generic prescription medication revenue in the U.S. from 2006 to 2018 (in billion U.S. dollars)*Brand and generic prescription medication revenue in the U.S. 2006-2018
- Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2018U.S. brand and generic prescription drug revenue 2005-2018
- Change in branded and generic medication spending in the United States from 2013 to 2018 (in billion U.S. dollars)*Spending change on branded and generic medicines in the U.S. 2013-2018
- Top generic drug companies by unbranded generics revenue in the U.S. in 2016-2017 (in billion U.S. dollars)*Unbranded generics revenue top corporations in U.S. 2016-2017
- Top companies based on unbranded generics U.S. market share during 2016-2017*Unbranded generics market share top corporations in U.S. 2016-2017
- Top 20 U.S. pharma products by dispensed prescriptions in 2018 (in millions)Top U.S. pharma products by prescriptions 2018
- Patent expiration
- Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)Projected sales at risk due to patent expiry 2009-2022
- Leading pharmaceutical companies based on sales loss due to patent risk until year-end 2018Top pharma companies by sales loss due to patent loss until 2018
- Forecast of new brand and brand loss of exclusivity (LOE) impact on growth in developed pharmaceutical markets from 2018 to 2022 (in billion U.S. dollars)*Forecast of new brand and LOE impact on growth of developed pharma markets 2018-2022
- Selected top branded biologic drugs in the United States that will go generic between 2016 and 2028, by revenue (in billion U.S. dollars)*Top branded biologic drugs in the U.S. that will go generic by 2028
- Time from launching a brand drug to meeting a paragraph IV patent challenge in the U.S. from 1995 to 2014Time from brand drug launch to generic patent challenges U.S. 1995-2014
- Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)Comparison of pre-expiry and generic price for drugs U.S. 2015
- Savings
- Savings through generic drug usage in the United States from 2008 to 2018 (in billion U.S. dollars)Savings through generic drug usage in the U.S. 2008-2018
- Top generic drugs based on savings in the United States in 2018 (in million U.S. dollars)Total savings of top generic drugs in U.S. 2018
- Cost savings through generics in the United States in 2018, by select therapeutic area (in billion U.S. dollars)*Saving of U.S. costs through generic pharmaceuticals by select therapy 2018
- Savings through generic drug usage in the United States in 2018, by age group (in billion U.S. dollars)Savings through generic drug usage in the U.S., by age group 2018
- Savings through generic drug usage in the United States in 2018, by payer (in billion U.S. dollars)Savings through generic drug usage in the U.S., by payer 2018
- Percentage of savings through generic drug usage in the United States in 2018, by payerPercentage savings through generic drug usage in the U.S. by payer 2018
- Percentage of savings through generic drug usage in the United States in 2018, by age groupSavings through generic drug usage in the U.S., by age group share 2018
- Biosimilars
- Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
- Number of biosimilars in development worldwide as of October 2017, by country Country-wise biosimilar pipelines number in development worldwide 2017
- Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)Reduction in U.S. direct spending on originator biologics as of 2018
- Filgrastim market share of Neupogen and its U.S. biosimilar competitors from 2015 to 2017Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2017
- Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017Share of insuline glargine sales Lantus vs. biosimilar US 2015-2017
- Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
- Example of physician office payment for biosimilars in Medicare Part B as of 2019 (in U.S. dollars)*Physician office payment for biosimilars in Medicare Part B in 2019
- Medicare savings through generic drug usage in the U.S. by state 2015
- Medicaid program savings through generic drug usage by U.S. state 2015
- Top generic entry drug savings in Canada by public drug plan 2012/2013
- Share of generic drugs in the pharmaceutical market in France 2016
- Generic substitution savings in France 2007-2014
- Generic market share value change worldwide 2006 vs. 2016, by region
- Generic market share change in unit volume worldwide 2006 vs. 2016, by region
- Generic share of dispensed prescriptions by formulation U.S. 2012 vs. 2017
- Share of top generic purchasing operations in U.S. 2017
- Spending on dispensed total vs. generic prescriptions in the U.S. 2017
- Generic drug savings forecast for Canada 2015-2017
- Annual growth of the global generic market 2009-2015 by region
- Price difference of a patented drug vs. its generic in selected countries 2010
- Dispensing costs for tablets of generic drugs by public drug plan 2017/18
- Sales volume of the largest-selling prescription drugs in Spain 2015
- New Zealand - types of owned financial products 2017-2018
- Gross savings as a share of GDP in Indonesia 2005-2017
- Value of private saving and term deposits in the Arab region 2016-2017
- Gross savings as a share of GDP in Singapore 2005-2017
- Gross savings as a share of GDP in Bangladesh 2005-2017
- Generics and biosimilars in Italy
- Generics and biosimilars
- 2019 Generic Drug & Biosimilars Access & Savings in the United States Report
- 2018 Generic Drug Access & Savings in the United States
- 2017 Generic Drug Access & Savings in the United States
- Generic Drugs in Canada, 2018
- Generic Drug Savings in the U.S. 2014
- Generic Drug Savings in the U.S. 2015
- 2016 Generic Drug Savings & Access Report in the United States
- Global Generic and Biosimilars Trends and Insights
- U.S. pharmaceutical industry
- Canadian pharmaceutical industry
- Pharmaceutical industry in Mexico
- Teva
- Generic Drugs in Canada, 2016
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
- Demographics
- Economy
- Education & Science
- Politics & Government
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
You can only download this statistic as a Premium user.
You can only download this statistic as a Premium user.
You can only download this statistic as a Premium user.
As a Premium user you get access to the detailed source references and background information about this statistic.
As a Premium user you get access to background information and details about the release of this statistic.
As soon as this statistic is updated, you will immediately be notified via e-mail.
...and make my research life easier.
You need at least a Premium Account to use this feature.
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.